CARE revises credit rating of Panacea Biotec’s long term bank facilities

31 Oct 2012 Evaluate

Credit Analysis & Research (CARE) has revised credit rating pertaining to Panacea Biotec’s long term bank facilities to B from BB and to A4 from A4 (under credit watch) in regard to short term bank facilities. B rating is applicable to instruments having tenure of more than one year and is considered to have high risk of default regarding timely servicing of financial obligations.

Meanwhile, A4 rating is applicable to instruments having tenure up to one year and is considered to have minimal degree of safety regarding timely payment of financial obligations. Such instruments carry very high credit risk and are susceptible to default.

Panacea Biotec is one of India’s leading research based health management companies with established research, manufacturing and marketing capabilities.

Panacea Biotec Share Price

522.95 24.90 (5.00%)
17-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1751.05
Dr. Reddys Lab 1163.70
Cipla 1515.45
Lupin 1936.75
Zydus Lifesciences 831.40
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...